Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 23.33 as of 2026-10-06T22:19:13.105Z.
Consensus retrieved: 2026-10-06T17:46:08.267Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:19:13.105Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7008baaa9815f858eb5331382464f7868386b07407f1e2e113b6b4da05b558f1
Forward PE Ratio (23.33) = Dated Quote Price ($44.65) / Consensus Forward EPS ($1.91)
FORWARD PE RATIO
23.33
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+18.13%
vs the sector median at left
Veracyte, Inc.
Market Cap
$3.56B
Forward PE Ratio
23.33
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Veracyte, Inc. (VCYT) | $3.56B | 23.33 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 32.05 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A |
Trailing P/E
31.9
reported TTM EPS
Forward P/E
23.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.91 implies +36.4% EPS growth vs the reported trailing $1.40.
At the dated quote price of $44.65, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.91 | $1.86 – $1.93 | 7 | 23.3x |
| 2027-12-31 | $1.95 | $1.92 – $1.98 | 7 | 22.9x |
| 2028-12-31 | $2.08 | $1.53 – $2.54 | 5 | 21.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
